A Pleasant Partnership (I Started a League Leader Group)
That's about it.
Two days later.
Inside a conference room at the Academy of Sciences.
Xu Yun gently put down the memo in his hand, looked at the crowd in front of him, and said:
"Personally, I'm inclined to have Chia Tai Tianqing discuss distribution cooperation with them. What are your opinions?"
At this very moment.
Sitting in front of Xu Yun were Lu Xiao, Tian Liangwei, Zheng Zu, Zhou Shan, and other senior executives of Huadun Biotech. After receiving the message from Xu Yun yesterday, they quickly took a flight to the capital.
Xu Yun then applied to the Chinese Academy of Sciences through Academician Pan for a meeting room for today's discussions.
"."
After listening to Xu Yun's introduction, Zheng Zu, the head of the USTC New Venture Fund, pondered for a moment:
"Dr. Xu, if we choose Chia Tai Tianqing as our distributor, how much will our distribution and sales volume slow down? -- I mean compared to those large local distributors in Europe and America."
As mentioned before.
Huadun Biotech's initial registered capital was 13 million Huaxia currency, which was fully subscribed in the first phase.
The lead investor in this round of funding was the USTC New Venture Fund, which injected 8 million Huaxia currency in cash flow and additional resources, acquiring a 27% stake.
The co-investors are the USTC School of Physics and the USTC School of Life Sciences), each contributing RMB 2 million in cash flow and additional resources, holding a 10% stake each, totaling 20%.
Xu Yun, an individual, invested 1 million yuan in cash, combining capital and technology, with the technology being fifth-generation Imidacloprid and its commercial derivatives, holding a 38% stake.
The remaining 15% is the employee stock option pool, used for ESOP rewards.
Meanwhile, Huadun Biotech adopts an AB shares structure, meaning that although Xu Yun only holds 38% of the shares, he actually possesses 90.1% of the voting rights.
In addition, Xu Yun's recent outstanding performance has brought him to the attention of the Academy's leadership and even higher levels. Therefore, in a sense, Xu Yun can make decisions about the company's future strategy quite independently.
However, since the New Venture Fund is also a shareholder of the company, Zheng Zu still needs to express his attitude in this situation.
"Sales volume due to distribution"
Xu Yun had already prepared for this question, and upon hearing it, he immediately looked at a man sitting next to Tian Liangwei:
"Manager Lin, please explain this aspect."
The man Xu Yun called Manager Lin was probably in his early fifties, with slightly graying temples, but he was well-maintained, with a square face and very light eyebrows. Generally speaking, lighter eyebrows can reduce the expression of emotions during communication, so many negotiation experts will deliberately groom their eyebrows.
This person's full name is Lin Feian, who is the junior of Tian Liangwei mentioned by Academician Pan, and is now the head of distribution for the medical project in Europe of Chia Tai Tianqing.
Lin Feian took over the Europe distribution business last December. The performance over the past period has been only mediocre. There's no way around it; China's pharmaceutical exports have always been weaker than imports, which is a problem of the overall economic environment.
The Board of Directors's requirement for Lin Feian was simply to first establish a presence in Europe and see if there was an opportunity to expand the medical consumables market a few years later. In a sense, this position was unlikely to cause any trouble, but it was also difficult to achieve any significant results.
Therefore, after his senior brother Tian Liangwei contacted him two days ago and informed him of the relevant situation, Lin Feian immediately rushed from Huadu to Beijing overnight to attend the meeting.
Lin Feian then coughed twice, stood up, nodded slightly to Xu Yun and Zheng Zu, and said:
"Dr. Xu, Chairman Zheng, to be frank, in terms of scale, our distribution channels and capabilities in Europe are definitely Chia Tai Tianqing than those of traditional local distributors."
"Currently, our group has 4,671 pharmaceutical chain partners in Europe, covering 53,224 stores and 1,202 hospitals and medical institutions, with a coverage rate of approximately 3.5 per 100,000 people."
"Last year, our shipments of various drugs reached 150 million doses. In terms of distribution channels, we accounted for approximately 28.5% of Boots' market share, and our shipment volume was approximately 23.8% of Boots'."
Xu Yun nodded slightly.
The Boots that Lin Feian mentioned is the largest international pharmaceutical, health and beauty group in the Britain, also known as United Bozi, and one of its subsidiaries is a skincare brand called Boots.
One of United Bozi's core businesses is pharmacies and the wholesale and distribution of pharmaceuticals, somewhat similar to local Neptune Chen or Kang Baijia Pharmacy, but much larger in scale, ranking among the top in Europe.
Lin Feian's willingness to use Boots as a comparison point demonstrates a relatively candid attitude. If it were any other distributors ranked outside the top ten, the resulting percentage would likely exceed 3%.
"Over twenty percent."
Upon hearing this, Zheng Zu frowned slightly and clicked his tongue softly.
"It seems a bit low."
As a businessman, Zheng Zu was more concerned about product sales than Xu Yun's preference for state-owned background.
After all, the company's financial statements are directly linked to his future prospects and financial future at the Academy of Sciences. The better Huadun Biotech's products sell, the higher his performance will naturally be.
Zheng Zu's goal is to be promoted from chairman of the foundation to head of a large enterprise under University of Science and Technology of China within three years. The current leader of that enterprise will retire in the summer of three years from now, and Zheng Zu is currently considered a strong contender for that position.
However, if the distribution speed slows down due to the distributors, even by half a year or so, the situation for Zheng Zu at that time will be unpredictable.
Of course.
Zheng Zu's thinking cannot be described as solely driven by profit. After all, everyone has their own needs and plans, and the question of whether to choose state-owned distributors should not be elevated to the level of a political stance.
"Chairman Zheng, please don't be in such a hurry."
Looking at Zheng Zu's hesitant expression, Lin Feian laughed instead:
"Chairman Zheng, our country's pharmaceutical export industry started developing relatively late, and there is also a significant technological gap between our country and foreign countries in terms of chemicals and pharmaceuticals. Therefore, our company's market share in Europe and the United States is not high, which is also due to external objective factors."
"Actually, it's not just Chia Tai Tianqing Pharmaceutical Group; the situation is similar for companies like Guangzhou Pharmaceutical Holdings Guosheng and Guosheng Pharmaceutical Group. The difference in data is only a few percent."
"Of course, these objective factors mainly affect distributors like us. Exporters like you haven't shared the pressure of this situation with us."
"At least, just talking about feelings isn't enough."
This time, many people in the meeting room nodded in agreement.
From the beginning until now, Lin Feian has been quite honest in his attitude, and has not resorted to moral blackmail or playing the personal card.
This might be due to Lin Feian's personality, or it might be a prepared script. In any case, people's impression of him is quite good so far.
Lin Feian then paused, picked up a document from in front of him, and continued:
"Distinguished directors, since you have no reason to help us unconditionally out of consideration for our relationship, the only thing we can offer you is financial incentive."
Lin Feian gently waved the document in his hand and explained:
"The document I have here is a letter of intent authorized to me by the CP Group before I came here. It lists some agreed-upon rates and commitments, and I'm sure it won't disappoint you."
After saying that, Lin Feian handed the document in his hand to Xu Yun's assistant, Tang Li.
Xu Yun gave Tang Li a wink, and Tang Li, understanding, placed it in front of Zheng Zu.
"."
Zheng Zu glanced at the thin stack of A4 paper, then looked up at Lin Feian, before turning the pages of the book.
The letter of intent was quite simple, since Huadun Biotech only wanted to export one product, and the license had already been issued. Therefore, most of the letter of intent directly concerned the product itself.
For example, Huadun Biotech needs to guarantee a certain number of products exported per year, the dosage per unit, and that the defect rate cannot exceed 0.03%, etc.
Then very quickly.
Zheng Zu then saw the relevant fee rates offered by Party B, namely Chia Tai Tianqing.
He had barely glanced at it when he looked up at Lin Feian in astonishment:
"Manager Lin, your distributor commission is only 11%? And that includes offshore shipping costs and insurance?"
Lin Feian smiled and nodded:
"That's right."
As is widely known.
Whether it's pharmaceuticals, food, or daily necessities, any large-scale cross-border trade involves enormous profits for the companies or individuals handling the transshipment.
The profits here mainly come from three aspects. The first is simple distribution commission, which means you provide the goods, I provide you with sales channels and distribution in the local area, and then I take a big cut from your profit or purchase price.
Secondly, there are transportation costs. Nowadays, bulk goods are usually transported by sea, and large dealerships often have rebate agreements with shipping companies. For example, rebates for large car dealerships can sometimes reach hundreds of thousands of US dollars.
Otherwise, there would be no concept of FOB and CIF prices in the commercial world.
Finally, there's the transportation insurance, which is also quite expensive, and many distributors specify which insurance company they partner with to purchase the insurance.
Unexpectedly...
In his letter of intent, Lin Feian surprisingly took on both transportation and insurance, with the distributor's commission being only 11% of the gross profit.
You need to know.
The USTC New Venture Fund has a subsidiary that produces carbamate insecticides, which are also exported to Europe. The German distributor, Vlitiego, which handles these projects, demands a commission as high as 38%.
It's no exaggeration to say...
After deducting transportation and insurance expenses, Chia Tai Tianqing will not lose money, but the profit will be very small.
Lin Feian clearly saw Zheng Zu's astonishment, and the corners of Xu Yun's senior brother's mouth couldn't help but curl up slightly.
As he said.
There is indeed a certain 'favor' between him and Huadun Biotech, but this favor only gives Lin Feian the qualification or opportunity to stand in this conference room; hoping to obtain the final contract based on this is unrealistic.
With sentimentality no longer an option, Chia Tai Tianqing can offer is sincerity.
Lin Feian's letter of intent came from the decision-making level of the CP Group and was a collective decision made by the CP Group after an emergency discussion.
Of course.
These concessions are not an attempt by the CP Group to curry favor with Huadun Biotech, but rather a strategic move for a longer-term purpose.
Today, the status of the CP Group, or more accurately, Huaxia's medical field, is rising globally, especially in the area of medical consumables, where Huaxia's annual export volume is increasing.
The reason for this situation is simple: it's due to the Huaxia paper.
The "cost" here refers not only to labor costs, but also to R&D costs and equipment costs. As a result, the cost of medical consumables has been compressed to a level that seems exaggerated in Europe and America.
It is foreseeable that in a few years or a decade or so, Huaxia's medical resources will inevitably launch a full-scale counterattack into the European and American markets.
In this scenario, if a large distributor with Huaxia connections exists, how much profit could it earn?
More importantly...
Nowadays, whether it's Guangzhou Pharmaceutical Holdings, Yangtze River Pharmaceutical Group, Guosheng, or Chia Tai Pharmaceutical Group, the shipment volumes of all state-owned distributors are almost the same, and for a period of time, the distributor rankings even changed every month.
[Yi Ge Lang Mie] is a revolutionary product with a disruptive impact. If CP Group can take advantage of the opportunity to distribute [Yi Ge Lang Mie] to expand its channels, then in the long run, it will not be as simple as just making a few percentage points of profit.
The CP Group had the vision and courage to invest in "Grand Variety Show" in the 1990s, and later launched the "Guinness China Night" series, demonstrating its strategic judgment.
Therefore, upon learning that Huadun Biotech was interested in them, CP Group immediately drafted this letter of intent.
"."
Looking at the clear terms and conditions on the letter of intent in front of him, Zheng Zu's expression was somewhat complicated.
What else could he say?
With distribution fees that are one-third lower than other companies, this alone is enough to make up for most of the disadvantages of limited distribution channels, not to mention freight and insurance.
Even combined, it might still not be as good as Boots, but at least there's no difference in scale.
In this situation, one is a state-owned enterprise, and the other is a wholly foreign-owned company. Is the answer even need to be stated?
Thinking about this...
Zheng Zu couldn't help but give a wry smile, and looked up with a hint of helplessness:
"Manager Lin, I must say, your offer is truly sincere, I have no objections."
Upon hearing this, Lin Feian's eyes immediately lit up with joy, but he maintained his composure on his face. Then he turned his head and looked at Xu Yun.
Xu Yun, understanding the implied meaning from the music, quickly looked at the other company directors:
What do other people think?
The remaining board members present were leaders from the USTC School of Physics and the USTC School of Life Sciences, and one was a member of the University of Science and Technology of China Board of Trustees. After hearing Xu Yun's words, they all expressed that they had no objections.
After all, Xu Yun and Zheng Zu both voted in favor, and the CP Group has indeed shown great sincerity. It would be unreasonable to disagree.
Seeing this, Xu Yun nodded in satisfaction, pondered for a moment, and then extended his hand to Lin Feian:
"In that case, Manager Lin, it's a pleasure to cooperate with you."
Lin Feian had been waiting for this moment for a long time. He could no longer suppress his smile and firmly grasped Xu Yun's hand:
"Dr. Xu, it's a pleasure working with you!"
Note:
At the request of several influential members, a new "Alliance Leader" group has been created. Those who meet the required follower count can join. The regular group has also been unlocked. The Alliance Leader group probably won't have many members, so there's no need to donate specifically to join.